Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 1998, p. 2602-2606, Vol. 42, No. 10
CLINPHARM SUPPORT GmbH,
Received 2 January 1998/Returned for modification 19 April
1998/Accepted 20 July 1998
The levels of degradation of cefetamet pivoxil (CAT), cefuroxime
axetil (CAE), and cefpodoxime proxetil (CPD) in 0.6 M phosphate buffer
(pH 7.4) and human intestinal juice (pH 7.4) at 37°C over 24 h
were compared. Significant differences in the time courses of
degradation and in the patterns of degradation products were observed.
(i) The relative proportions of the
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Stability of Cephalosporin Prodrug Esters in Human
Intestinal Juice: Implications for Oral Bioavailability
2- and
3-cephalosporins were
roughly reversed in the two incubation media. In phosphate buffer, the
major degradation product was the
2-cephalosporin (CAT = 61%;
CAE = 74%; CPD = 85%), while in intestinal juice it was the
3-cephalosporin (CAT = 86%; CAE = 75%; CPD = 87%).
(ii) Generally, the degradation of the prodrug esters progressed faster in intestinal juice than in phosphate buffer (e.g., for CAT the half-lives [t1/2s] were 0.78 and 4.3 h,
respectively). (iii) The two diastereoisomers of CAE and CPD
were degraded at different rates in intestinal juice (for the CAE
diasteroisomers, t1/2s = 0.37 and
0.93 h; for the CPD diastereoisomers,
t1/2s = 0.18 and 0.98 h) but were
degraded at similar rates in phosphate buffer (for the CAE
diastereoisomers, t1/2 = 1.6 h; for the
CPD t1/2 diastereoisomers, = 2.2 h). It is
concluded that (i) the
2 isomerization does not significantly affect
the bioavailability of prodrug esters since enzymatic hydrolysis in the
intestinal fluid proceeds mainly to the active
3-cephalosporin and
(ii) the high degree of stereoselectivity of the enzymatic ester
hydrolysis should make it possible to increase the bioavailabilities of
certain prodrug esters (CAE, CPD) by using the more stable
diasterioisomer.
*
Corresponding author. Mailing address: CLINPHARM
SUPPORT GmbH, Leimenstrasse 57, CH-4051 Basel, Switzerland.
Phone: 41 61 274 07 47. Fax: 41 61 274 07 48. E-mail:
100271,1114{at}compuserve.com.
Antimicrobial Agents and Chemotherapy, October 1998, p. 2602-2606, Vol. 42, No. 10
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»